Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sinopharm Group Co ( (HK:1099) ) has shared an update.
Sinopharm Group Co. Ltd. announced preliminary financial results for its subsidiary, Sinopharm Accord, for the first half of 2025, showing a slight decline in revenue and profit compared to the same period last year. Despite a decrease in net profit and earnings per share, the company’s total assets and equity attributable to shareholders saw an increase, indicating a stable financial position amidst challenging market conditions.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the pharmaceutical industry, focusing on the distribution and retail of pharmaceutical products and medical devices. The company is a key player in the Chinese market, with its subsidiary Sinopharm Accord listed on the Shenzhen Stock Exchange.
Average Trading Volume: 6,092,614
Technical Sentiment Signal: Buy
Current Market Cap: HK$59.41B
See more insights into 1099 stock on TipRanks’ Stock Analysis page.